JP2018522847A5 - - Google Patents

Download PDF

Info

Publication number
JP2018522847A5
JP2018522847A5 JP2017564846A JP2017564846A JP2018522847A5 JP 2018522847 A5 JP2018522847 A5 JP 2018522847A5 JP 2017564846 A JP2017564846 A JP 2017564846A JP 2017564846 A JP2017564846 A JP 2017564846A JP 2018522847 A5 JP2018522847 A5 JP 2018522847A5
Authority
JP
Japan
Prior art keywords
tetrahydro
pyridin
oxo
phenylamino
indole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2017564846A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018522847A (ja
Filing date
Publication date
Priority claimed from PCT/EP2015/063527 external-priority patent/WO2015193339A1/en
Application filed filed Critical
Priority claimed from PCT/EP2016/063540 external-priority patent/WO2016202755A1/en
Publication of JP2018522847A publication Critical patent/JP2018522847A/ja
Publication of JP2018522847A5 publication Critical patent/JP2018522847A5/ja
Withdrawn legal-status Critical Current

Links

JP2017564846A 2015-06-17 2016-06-14 3−アミノ−1,5,6,7−テトラヒドロ−4h−インドール−4−オン類 Withdrawn JP2018522847A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
PCT/EP2015/063527 WO2015193339A1 (en) 2014-06-17 2015-06-17 3-amino-1,5,6,7-tetrahydro-4h-indol-4-ones
EP15172613 2015-06-17
EP15172613.0 2015-06-17
EPPCT/EP2015/063527 2015-06-17
EP15177393 2015-07-17
EP15177393.4 2015-07-17
PCT/EP2016/063540 WO2016202755A1 (en) 2015-06-17 2016-06-14 3-amino-1,5,6,7-tetrahydro-4h-indol-4-ones

Publications (2)

Publication Number Publication Date
JP2018522847A JP2018522847A (ja) 2018-08-16
JP2018522847A5 true JP2018522847A5 (enExample) 2019-04-04

Family

ID=57545595

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017564846A Withdrawn JP2018522847A (ja) 2015-06-17 2016-06-14 3−アミノ−1,5,6,7−テトラヒドロ−4h−インドール−4−オン類

Country Status (8)

Country Link
US (1) US10227299B2 (enExample)
EP (1) EP3310775B1 (enExample)
JP (1) JP2018522847A (enExample)
CN (1) CN107922389A (enExample)
CA (1) CA2989469A1 (enExample)
TW (1) TW201718534A (enExample)
UY (1) UY36737A (enExample)
WO (1) WO2016202755A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015193339A1 (en) * 2014-06-17 2015-12-23 Bayer Pharma Aktiengesellschaft 3-amino-1,5,6,7-tetrahydro-4h-indol-4-ones
CN107406417B (zh) 2015-01-28 2020-06-09 拜耳制药股份公司 4H-吡咯并[3,2-c]吡啶-4-酮衍生物
WO2018158175A1 (en) 2017-02-28 2018-09-07 Bayer Pharma Aktiengesellschaft Combination of bub1 inhibitors
EP4217070A1 (en) 2020-09-23 2023-08-02 Scorpion Therapeutics, Inc. Pyrrolo[3,2-c]pyridin-4-one derivatives useful in the treatment of cancer
TW202229282A (zh) 2020-09-30 2022-08-01 美商史考皮恩治療有限公司 治療癌症之方法
WO2022072645A2 (en) 2020-09-30 2022-04-07 Scorpion Therapeutics, Inc. Methods for treating cancer
AU2021358123A1 (en) 2020-10-05 2023-06-08 Enliven Inc. 5- and 6-azaindole compounds for inhibition of bcr-abl tyrosine kinases
JP2023548657A (ja) 2020-10-09 2023-11-20 スコーピオン セラピューティクス インコーポレイテッド がんの処置に使用するための、egfrおよび/またはher2のヘテロ環阻害剤
WO2022094271A1 (en) 2020-10-30 2022-05-05 Scorpion Therapeutics, Inc. Methods for treating cancer
WO2022098992A1 (en) 2020-11-05 2022-05-12 Scorpion Therapeutics, Inc. Use of macrocyclic compounds in methods of treating cancer
WO2022197913A1 (en) 2021-03-18 2022-09-22 Scorpion Therapeutics, Inc. Bicyclic derivatives which can be used to treat cancer
WO2023173083A1 (en) 2022-03-11 2023-09-14 Scorpion Therapeutics, Inc. Tetrahydroindole derivatives as egfr and/or her2 inhibtors useful for the treatment of cancer
WO2024159094A1 (en) * 2023-01-27 2024-08-02 Enliven Inc. Pyrimidinyl (hetero)aromatic aminopyridine compounds for inhibition of raf kinases
WO2024254266A1 (en) 2023-06-08 2024-12-12 Scorpion Therapeutics, Inc. A 1,5-dihydro-4h-pyrrolo[3,2-c] pyridin-4-one for use in the treatment of cancer
WO2024254298A1 (en) 2023-06-08 2024-12-12 Scorpion Therapeutics, Inc. A 1,5-dihydro-4h-pyrrolo[3,2-c] pyridin-4-one for use in the treatment of cancer

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA111754C2 (uk) * 2011-10-06 2016-06-10 Байєр Фарма Акцієнгезелльшафт Заміщені бензиліндазоли для застосування як інгібіторів bub1-кінази для лікування гіперпроліферативних захворювань
JP6141866B2 (ja) 2011-12-21 2017-06-07 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH 置換ベンジルピラゾール類
HK1207861A1 (en) * 2012-05-11 2016-02-12 Bayer Pharma Aktiengesellschaft Substituted cycloalkenopyrazoles as bub1 inhibitors for the treatment of cancer
EP2976336A1 (en) 2013-03-21 2016-01-27 Bayer Pharma Aktiengesellschaft 3-heteroaryl substituted indazoles
WO2014147204A1 (en) 2013-03-21 2014-09-25 Bayer Pharma Aktiengesellschaft Heteroaryl substituted indazoles
EP3010911A1 (en) 2013-06-21 2016-04-27 Bayer Pharma Aktiengesellschaft Heteroaryl substituted pyrazoles
JP2016525076A (ja) 2013-06-21 2016-08-22 バイエル ファーマ アクチエンゲゼルシャフト 置換されたベンジルピラゾール類
EP3010901B1 (en) 2013-06-21 2017-09-13 Bayer Pharma Aktiengesellschaft Heteroaryl substituted pyrazoles
EP3010902A1 (en) 2013-06-21 2016-04-27 Bayer Pharma Aktiengesellschaft Substituted benzylpyrazoles
WO2015063003A1 (en) 2013-10-30 2015-05-07 Bayer Pharma Aktiengesellschaft Heteroaryl substituted pyrazoles
WO2015193339A1 (en) 2014-06-17 2015-12-23 Bayer Pharma Aktiengesellschaft 3-amino-1,5,6,7-tetrahydro-4h-indol-4-ones
CN107406417B (zh) 2015-01-28 2020-06-09 拜耳制药股份公司 4H-吡咯并[3,2-c]吡啶-4-酮衍生物
EP3331611B1 (en) * 2015-08-05 2021-06-02 Bayer Pharma Aktiengesellschaft 1h-pyrrol-3-amines
CA3008393A1 (en) 2015-12-16 2017-06-22 Bayer Pharma Aktiengesellschaft Hetero-1,5,6,7-tetrahydro-4h-indol-4-ones

Similar Documents

Publication Publication Date Title
JP2018522847A5 (enExample)
CN109641844B (zh) 整合应激通路的调节剂
JP2017530185A5 (enExample)
HRP20212000T1 (hr) Aminotriazolopiridini kao inhibitori kinaze
JP2020506946A5 (enExample)
JP2016517878A5 (enExample)
HRP20130106T1 (hr) Imidazotriazini i imidazopirimidini kao inhibitori kinaze
JP2016523911A5 (enExample)
RU2017121044A (ru) Производные амидотиадиазола в качестве ингибиторов надфн-оксидазы
JP2013523889A5 (enExample)
RU2348628C2 (ru) Замещенные циклопропильной группой оксазолидиноновые антибиотики и их производные
HRP20141093T1 (hr) Triazolopirimidini
HRP20191821T1 (hr) Antiproliferativni spojevi i načini njihove uporabe
HRP20201469T1 (hr) Derivati tetrahidroizokinolina
IL264982B (en) (hetero)aryl cyclopropylamine compounds as lsd1 inhibitors
JP2019505541A5 (enExample)
HRP20210143T1 (hr) 2-heteroaril-3-okso-2,3-dihidropiridazin-4-karboksamidi za liječenje raka
JP2016503009A5 (enExample)
RU2005108999A (ru) Азотсодержащие ароматические производные
JP2017537948A5 (enExample)
RU2016141645A (ru) ИНГИБИТОРЫ TrkA КИНАЗЫ, ОСНОВАННЫЕ НА НИХ КОМПОЗИЦИИ И СПОСОБЫ
RU2014147243A (ru) Производные пирролопиридинона в качестве ttx-s блокаторов
JP2017508766A5 (enExample)
RU2016110483A (ru) Производные пирролопиридина или пиразолопиридина
JP2018536686A5 (enExample)